

## BELGIUM

### Recent and planned developments in pharmaceutical policies 2014 Policies related to high cost medicines

D E V E L O P M E N T S	<b>Changes in pricing</b>	<b>Changes in reimbursement</b>
	<p>2015:</p> <p>Reference reimbursement system: Extra reduction reimbursement level 6 years after cluster opening (-6,5%) Implemented as from 01.03.2015</p> <p>Ceiling price for telmisartan/escitalopram/anti-Alzheimer</p> <p>No indexation basic fee pharmacist</p> <p>New generics – entries after cluster opening: reimbursement level in range of “cheapest” medicines (= <i>lowest reimbursement level + 5 % range</i>)</p>	<p>2015:</p> <p>No annual indexation co-payment ceilings</p>
	<b>Other changes</b>	
	<ul style="list-style-type: none"> <li>• <i>prescription monitoring (2015):</i> <p>change in the definition of “cheap” medicines: “cheap” → “cheapest” Prescription: brand name or INN Only molecules in reference price system</p> </li> <li>• <i>volume control (2015):</i> <p>Still to be negotiated – proposals:</p> <ul style="list-style-type: none"> <li>- Feedback prescription monitoring (+ analysis outliers)</li> <li>- Medico-pharmaceutical consultation</li> <li>- Information campaign (antibiotics)</li> <li>- Pack sizes versus length of treatment</li> <li>- Polymedication</li> </ul> </li> <li>• <i>TPU (01.04.2015):</i> <p>Introduction of a tarification per unit per week for oral-solid pharmaceuticals dispensed by pharmacists (out-patient sector) to patients in residential care (royal decrees published – implementation period foreseen) :</p> <ul style="list-style-type: none"> <li>• new reimbursement level per unit</li> <li>• new co-payment per unit</li> <li>• new average dispensing fee per week for pharmacists</li> </ul> </li> </ul>	

S P E C I A L  T O P I C	<h3>High cost medicines</h3>
	<ul style="list-style-type: none"><li>• <u>Special pricing policies:</u></li></ul>
	<ul style="list-style-type: none"><li>• <u>Special reimbursement/funding policies:</u></li></ul>
	“managed entry agreements”:
	- “risk sharing”
	- “conditional with observational study”
	Chapter IV reimbursement (prior authorization) Orphan colleges
	<ul style="list-style-type: none"><li>• <u>High cost medicines at the interface of out-patient and in-patient sectors:</u></li></ul>
	-
	<ul style="list-style-type: none"><li>• <u>Key challenges and solutions:</u></li></ul>
Maintaining a balance between solidarity and innovation requires a permanent and transparent mobilization of all social and democratic forces on a national, European and global level	